Focus Partners Advisor Solutions LLC Cuts Stock Holdings in Eli Lilly and Company $LLY

Focus Partners Advisor Solutions LLC lessened its position in Eli Lilly and Company (NYSE:LLY) by 4.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,410 shares of the company’s stock after selling 552 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Eli Lilly and Company were worth $10,232,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Exencial Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 189.6% in the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after purchasing an additional 11,396 shares in the last quarter. Rede Wealth LLC purchased a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $487,000. Central Pacific Bank Trust Division boosted its position in Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after buying an additional 1,843 shares during the period. Cidel Asset Management Inc. grew its stake in shares of Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after acquiring an additional 5,591 shares in the last quarter. Finally, Oak Family Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the third quarter worth $1,979,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,017.97 on Tuesday. The company has a market capitalization of $960.31 billion, a price-to-earnings ratio of 44.36, a price-to-earnings-growth ratio of 1.22 and a beta of 0.40. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The stock has a 50 day moving average price of $1,051.98 and a 200 day moving average price of $934.28.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter last year, the company earned $5.32 earnings per share. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on LLY shares. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Royal Bank Of Canada initiated coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price objective for the company. Berenberg Bank boosted their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research report on Thursday, February 19th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,229.59.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: LLY is preparing to launch its oral obesity drug, orforglipron, in the U.S. as early as Q2 pending FDA approval — a major new revenue stream if approved and launched on schedule. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: CHMP has backed expanding Olumiant (baricitinib) to treat adolescents with severe alopecia areata; a final EU approval would broaden the drug’s market. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Recent analyst upgrades and filings show institutional buying and at least one upgrade that briefly lifted the stock — signals of continued investor confidence among some large holders. Eli Lilly and Company (NYSE:LLY) Stock Price Up 2.8% on Analyst Upgrade
• Positive Sentiment: “Smart money” accumulation noted during a YTD pullback suggests institutional investors are using weakness to add exposure. What Smart Money Loves About Lilly
• Neutral Sentiment: Management presented at TD Cowen’s healthcare conference — transcripts may contain pipeline and commercial execution detail but revealed no market-moving surprises in headlines. Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Analyst consensus remains around a “moderate buy,” reflecting broadly positive views but tempered expectations given valuation. Eli Lilly and Company (NYSE:LLY) Receives Average Recommendation of “Moderate Buy” from Analysts
• Negative Sentiment: Competitive pressure: Novo Nordisk’s $506M Ireland plant expansion is aimed at boosting capacity for oral GLP-1 medicines, which could help Novo defend share against Lilly in weight-loss/diabetes markets. Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
• Negative Sentiment: Valuation debate: multiple investor pieces flag Lilly’s high valuation after a multi-year run, suggesting limited upside absent continued blockbuster launches and execution. Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock?

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.